Jump to content

Fasoracetam: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
No edit summary
No edit summary
Line 52: Line 52:
'''Fasoracetam''' is a [[research chemical]] of the [[racetam]] family.<ref>{{cite web |url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=198695|title=5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary|accessdate=21 July 2013}}</ref> It is a putative [[nootropic]] that failed to show sufficient [[efficacy]] in clinical trials for [[vascular dementia]]. It is currently being studied for its potential use for [[attention deficit hyperactivity disorder]].<ref name=adis/><ref>{{cite journal|title=Recommended INN List 40|journal=WHO Drug Information|date=1998|volume=12|issue=2|url=https://mednet-communities.net/inn/db/media/docs/r-innlist40.pdf}}</ref>
'''Fasoracetam''' is a [[research chemical]] of the [[racetam]] family.<ref>{{cite web |url=https://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=198695|title=5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary|accessdate=21 July 2013}}</ref> It is a putative [[nootropic]] that failed to show sufficient [[efficacy]] in clinical trials for [[vascular dementia]]. It is currently being studied for its potential use for [[attention deficit hyperactivity disorder]].<ref name=adis/><ref>{{cite journal|title=Recommended INN List 40|journal=WHO Drug Information|date=1998|volume=12|issue=2|url=https://mednet-communities.net/inn/db/media/docs/r-innlist40.pdf}}</ref>


Fasoracetam appears to agonize all three [[metabotropic glutamate receptor]]s and has improved cognitive function in [[animal testing on rodents|rodent studies]].<ref name=Connolly/> It is [[orally bioavailable]] and is excreted mostly unchanged via the urine.<ref>{{cite journal|last1=Malykh|first1=AG|last2=Sadaie|first2=MR|title=Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.|journal=Drugs|date=12 February 2010|volume=70|issue=3|pages=287–312|doi=10.2165/11319230-000000000-00000|pmid=20166767}}</ref>
Fasoracetam appears to agonize all three groups of [[metabotropic glutamate receptor]]s and has improved cognitive function in [[animal testing on rodents|rodent studies]].<ref name=Connolly/> It is [[orally bioavailable]] and is excreted mostly unchanged via the urine.<ref>{{cite journal|last1=Malykh|first1=AG|last2=Sadaie|first2=MR|title=Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.|journal=Drugs|date=12 February 2010|volume=70|issue=3|pages=287–312|doi=10.2165/11319230-000000000-00000|pmid=20166767}}</ref>


Fasoracetam was discovered by scientists at the Japanese pharmaceutical company [[Nippon Shinyaku]], which brought it through Phase 3 clinical trials for [[vascular dementia]], and abandoned it due to lack of efficacy.<ref name=Connolly>{{cite journal |title=ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder. | volume=49 | issue=5 | journal=Ther Innov Regul Sci | pages=632–642 | last1 = Connolly| first1 = J | last2 = Glessner | first2 = J | last3 = Kao | first3 = C | last4 = Elia | first4 = J | last5 = Hakonarson | first5 = H | doi=10.1177/2168479015599811|pmid=26366330|pmc=4564067}}</ref><ref name=Hoskowitz>{{cite book|last1=Moskowitz|first1=D. H.|title=Finding the Genetic Cause and Therapy for ADHD, Autism and 22q|date=2017|publisher=BookBaby (self published)|isbn=9781483590981|url=https://books.google.com/books?id=LSrlDQAAQBAJ&pg=PT117|language=en}}</ref>
Fasoracetam was discovered by scientists at the Japanese pharmaceutical company [[Nippon Shinyaku]], which brought it through Phase 3 clinical trials for [[vascular dementia]], and abandoned it due to lack of efficacy.<ref name=Connolly>{{cite journal |title=ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder. | volume=49 | issue=5 | journal=Ther Innov Regul Sci | pages=632–642 | last1 = Connolly| first1 = J | last2 = Glessner | first2 = J | last3 = Kao | first3 = C | last4 = Elia | first4 = J | last5 = Hakonarson | first5 = H | doi=10.1177/2168479015599811|pmid=26366330|pmc=4564067}}</ref><ref name=Hoskowitz>{{cite book|last1=Moskowitz|first1=D. H.|title=Finding the Genetic Cause and Therapy for ADHD, Autism and 22q|date=2017|publisher=BookBaby (self published)|isbn=9781483590981|url=https://books.google.com/books?id=LSrlDQAAQBAJ&pg=PT117|language=en}}</ref>

Revision as of 03:24, 29 January 2019

Fasoracetam
Names
IUPAC name
(5R)-5-(Piperidine-1-carbonyl)pyrrolidin-2-one
Other names
(5R)-5-Oxo-D-prolinepiperidinamide monohydrate, NS-105, AEVI-001, LAM 105, MDGN-001, NFC 1[1][2]
Identifiers
3D model (JSmol)
ChEMBL
ChemSpider
KEGG
  • InChI=1S/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1 checkY
    Key: GOWRRBABHQUJMX-MRVPVSSYSA-N checkY
  • InChI=1/C10H16N2O2/c13-9-5-4-8(11-9)10(14)12-6-2-1-3-7-12/h8H,1-7H2,(H,11,13)/t8-/m1/s1
    Key: GOWRRBABHQUJMX-MRVPVSSYBL
  • O=C(N1CCCCC1)[C@@H]2NC(=O)CC2
Properties
C10H16N2O2
Molar mass 196.250 g·mol−1
Pharmacology
Oral
Legal status
  • US: Not FDA approved
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
☒N verify (what is checkY☒N ?)

Fasoracetam is a research chemical of the racetam family.[3] It is a putative nootropic that failed to show sufficient efficacy in clinical trials for vascular dementia. It is currently being studied for its potential use for attention deficit hyperactivity disorder.[2][4]

Fasoracetam appears to agonize all three groups of metabotropic glutamate receptors and has improved cognitive function in rodent studies.[5] It is orally bioavailable and is excreted mostly unchanged via the urine.[6]

Fasoracetam was discovered by scientists at the Japanese pharmaceutical company Nippon Shinyaku, which brought it through Phase 3 clinical trials for vascular dementia, and abandoned it due to lack of efficacy.[5][7]

Scientists at Children's Hospital of Philadelphia led by Hakon Hakonarson have studied fasoracetam's potential use in attention deficit hyperactivity disorder.[5] Hakonarson started a company called neuroFix Therapeutics to try to bring the drug to market for this use; neuroFix acquired Nippon Shinyaku's clinical data as part of its efforts.[7][8] neuroFix was acquired by Medgenics in 2015.[8] Medgenics changed its name to Aevi Genomic Medicine in 2016.[9] Clinical trials in adolescents with ADHD who also have mGluR mutations started in 2016.[8]

See also

References

  1. ^ FDA/NIH Substance registration system. Page accessed March 21, 2016
  2. ^ a b "Drug Profile Fasoracetam".
  3. ^ "5-oxo-D-prolinepiperidinamide monohydrate - Compound Summary". Retrieved 21 July 2013.
  4. ^ "Recommended INN List 40" (PDF). WHO Drug Information. 12 (2). 1998.
  5. ^ a b c Connolly, J; Glessner, J; Kao, C; Elia, J; Hakonarson, H. "ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder". Ther Innov Regul Sci. 49 (5): 632–642. doi:10.1177/2168479015599811. PMC 4564067. PMID 26366330.
  6. ^ Malykh, AG; Sadaie, MR (12 February 2010). "Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders". Drugs. 70 (3): 287–312. doi:10.2165/11319230-000000000-00000. PMID 20166767.
  7. ^ a b Moskowitz, D. H. (2017). Finding the Genetic Cause and Therapy for ADHD, Autism and 22q. BookBaby (self published). ISBN 9781483590981.
  8. ^ a b c Sharma, B. "Medgenics: NFC-1 Could Be A Key Future Revenue Driver".
  9. ^ "Press Release: Medgenics, Inc. Announces Name Change to Aevi Genomic Medicine, Inc". Aevi via MarketWired. 16 December 2016.
Retrieved from "https://en.wikipedia.org/enwiki/w/index.php?title=Fasoracetam&oldid=880730401"